What economic evaluations have been conducted to compare the effectiveness of monitoring with repeated biomarker measurement (BNP, NT-proBNP or troponin) or repeated cardiac imaging (echocardiography or cardiac MRI) to usual care without repeated measurement or imaging in people with atrial fibrillation and heart failure?
No economic evaluations were identified for the comparison of the effectiveness of monitoring with repeated biomarker measurement (BNP, NT-proBNP or troponin) or repeated cardiac imaging (echocardiography or cardiac MRI) to usual care without repeated measurement or imaging in people with atrial fibrillation and heart failure.